Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

603
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
603
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

741
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
741
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

566
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
566
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

695
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
695
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

706
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
706
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

405
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
405

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients.

The American journal of cardiology·2026
Same author

Diagnostic Performance and Interpreter Experience of 1-Hour Versus 3-Hour <sup>99m</sup>Tc-HMDP Cardiac Amyloid Radionuclide Imaging: A Prospective, Blinded Comparison.

Circulation. Cardiovascular imaging·2025
Same author

Comparative performance of <sup>99m</sup>Tc-pyrophosphate vs. <sup>99m</sup>Tc-hydroxymethylene diphosphonate for cardiac amyloid radionuclide imaging.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2025
Same author

Refining Carotid Stenting Through Mesh-Integrated Stent Design.

JACC. Cardiovascular interventions·2025
Same author

Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.

European heart journal·2025
Same author

Delayed-Onset ICI-Associated Myocarditis: When Immunotherapy's Cardiac Consequences Outlast Treatment.

JACC. Case reports·2025

Video Experimental Relacionado

Updated: Mar 11, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Cardiomiopatía obstructiva hipertrófica

Josef Veselka1, Nandan S Anavekar2, Philippe Charron3

  • 1Department of Cardiology, 2nd Medical School, Charles University and Motol University Hospital, Prague, Czech Republic.

Lancet (London, England)
|December 4, 2016
PubMed
Resumen

La cardiomiopatía obstructiva hipertrófica (HOCM) es una enfermedad hereditaria del músculo cardíaco que causa el engrosamiento de las paredes del corazón y la obstrucción del flujo de salida. El diagnóstico incluye evaluación clínica e imágenes, con tratamientos como desfibriladores o terapia de reducción septal para casos graves.

Más Videos Relacionados

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

18.0K

Videos de Experimentos Relacionados

Last Updated: Mar 11, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

18.0K

Área de la Ciencia:

  • Cardiología
  • La genética
  • Médico interno

Sus antecedentes:

  • La cardiomiopatía obstructiva hipertrófica (HOCM) es una enfermedad miocárdica hereditaria primaria.
  • Se caracteriza por hipertrofia cardíaca (espesor de pared ≥15 mm) no relacionada con condiciones de carga anormales.
  • La obstrucción del tracto de salida del ventrículo izquierdo (LVOTO) es una característica clave, definida como ≥30 mm Hg.

Objetivo del estudio:

  • Para definir las características clave de la miocardiopatía obstructiva hipertrófica.
  • Para delinear los enfoques de diagnóstico para HOCM.
  • Resumir las estrategias actuales de gestión de la HOCM y sus complicaciones.

Principales métodos:

  • El diagnóstico generalmente se sospecha basado en la presentación clínica.
  • Las modalidades de imagen son cruciales para la confirmación y evaluación de la gravedad.
  • La estratificación del riesgo de muerte súbita cardíaca y otras complicaciones es esencial.

Principales resultados:

  • Los síntomas comunes incluyen disnea, dolor en el pecho, palpitaciones y síncope.
  • Los pacientes se enfrentan a un mayor riesgo de muerte súbita cardíaca, insuficiencia cardíaca y fibrilación auricular.
  • Existen estrategias efectivas de gestión para los riesgos y síntomas identificados.

Conclusiones:

  • La HOCM requiere un diagnóstico y una evaluación de riesgos rápidos.
  • El tratamiento implica terapias dirigidas, como la implantación de un desfibrilador cardioverter para el riesgo de muerte cardíaca súbita.
  • Se recomienda la terapia de reducción septal (mictomía o ablación septal por alcohol) para los síntomas graves de LVOTO.
  • La anticoagulación de por vida está indicada después de episodios de fibrilación auricular.